Oxford Nanopore Technologies Plc · LSE:ONT
Oxford Nanopore Technologies — J.P. Morgan Healthcare Conference 2025
27 slides from Oxford Nanopore Technologies's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference 13 January 2025 Gordon Sanghera, CEO
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Oxford Nanopore Technologies plc (“Oxford Nanopore”) Oxford Nanopore products are not intended for use for health assessment or to diagnose, treat, for information purposes only and does not constitute an offer of, or solicitation to purchase or miti
Slide 3: Our vision is to enable the analysis of anything, by anyone, anywhere
Our vision is to enable the analysis of anything, by anyone, anywhere We empower people to explore and answer biological questions with our transformative technology platform Any community Any environment And, Space
Slide 4: A new generation of single molecule sensing
A new generation of single molecule sensing Features address unmet needs: global reach for substantial global opportunity Multi-Omics platform: • Genomics • Epigenetics • Transcriptomics Proteomics, metabolomics in development Validated technology: >14,000 Customer Publications Sustainable growth co
Slide 5: Robust FY24 performance
Robust FY24 performance ~31% H2’24 preliminary numbers Underlying revenue £183m 3YR CAGR £170m £147m ~£99m ~34% H2 revenue H2 underlying growth at CC £127m FY’24 preliminary numbers ~£183m ~23% FY24 revenue FY24 underlying growth at CC 2021 2022 Underlying revenue 2023 COVID EGP 2024E ~74% revenue f
Slide 6: Growing our four core end-markets
Growing of our four core end-markets Revenue by customer type end-market1 Applied Industrial ~13% Customers utilising sequencing for application in industrial or service setting e.g. outsourced Synthetic Biology Clinical ~9% Research2 ~70% Customers where data may have Customers funded to research n
Slide 7: Key 2024 innovation milestones
Key 2024 innovation milestones Delivering growth in 2024 and beyond Driving adoption and utilisation Driving adoption and utilization by Growing our applied markets in research markets with new increasing platform capabilities and product offering as we prepare instrument launches releasing end-to-e
Slide 8: Medium term outlook: FY27 targets
Medium term outlook: FY27 targets >30% CAGR1 >62% 2027 Revenue Gross margin Adjusted EBITDA Medium term revenue Material scope for margin Breakeven profitability in FY27 with growth underpinned by improvement over the operational leverage set to improve further differentiated technology medium term
Slide 9: Key performance drivers
Key performance drivers Highly differentiated Innovation Commercial expansion Operational platform drives adoption engine drives delivering on our growth execution to meet growth growth commitment plans Releasing new platform Richer insights capabilities, products, Increased sales, support team Scal
Slide 10: Our platform is designed to drive sustainable growth
Our platform is designed to drive sustainable growth Built on an evergreen IP portfolio of >2,500 Patents and patent applications • Direct / Native sequencing of any DNA or Motor Run conditions (Buffers, software) RNA fragment Protein, small molecule sensing in development Nanopore • ML based algori
Slide 11: Three key benefits driving adoption
Three key benefits driving adoption Richer insights Faster time to result Accessible & affordable Highly accurate, Multi-omic data on a single tech Near-sample, real-time workflows Scalability that enables every application captures more types of genetic variation that don’t require batching by broa
Slide 12: Richer biological data: full genomic insights in one analysis
Richer biological data: full genomic insights in one analysis Multi-omic view of DNA Epigenetics Cancer, complex Small variants disease, plants Sickle cell disease, Cystic fibrosis Larger, more Dark genome complex variants Clinically and Alzheimer’s, Parkinson’s scientifically relevant regions Base
Slide 13: Paving the way for new standards in human genetics
Paving the way for new standards in human genetics Legacy technologies Oxford Nanopore delivers: Creating a can miss: new standard: • True reference genomes with a • ~8% of human genome single tech - T2T • 13% increase in Dx yield vs negative short read genomes 3 • As much as half Structural Variati
Slide 14: We are on our translational journey
We are on our translational journey Human & Infectious Disease Discovery Translation Translation Translation Translation science to humans to patients into practice to community Breakthrough Forging new ground Move to specialist Deploy in Next generation research in clinical research centres most ho
Slide 15: 2024 Breakthrough research programmes
Methylation case studies 2024 Breakthrough research programmes Human Genetics, Cancer, Rare Disease PRECISE, Singapore Genomics England • 10,000 Oxford Nanopore genomes • ~ 7,500 samples • To improve understanding of genetic • To improve diagnostic outcomes diversity in Malay, Indian and Chinese rar
Slide 16: 2024 Breakthrough translational studies
Methylation case studies 2024 Breakthrough translational studies Human Genetics, Oncology, Rare Disease Al Jalila Children's Hospital Rapid tumour methylation profiling • Identified rare diseases in a further 13% of cases unresolved with • Multiple centres incl. UK, Europe, USA short reads • CNS tum
Slide 17: 2024 Breakthrough studies moving into practice
2024 Breakthrough studies moving into practice Infectious disease examples NHS expansion Respiratory Metagenomics AmPORE TB to as many as 30 sites from 2024 Expanding to 30 Launching in 2025 NHS UK sites from 2024 with BioMerieux Global potential • UK expansion follows pilots • AmporeTB added to glo
Slide 18: Providing solutions across the BioPharma pipeline
Providing solutions across the BioPharma pipeline Accelerating the personalised medicine revolution R&D drug discovery Development & clinical trials Biomanufacturing & commercial Discovering novel biomarkers, novel targets, Adopting methods for drug Regulated use of validated methods for both novel
Slide 19: 2024 Key steps forward in BioPharma
2024 Key steps forward in BioPharma Building the network Network Building Launched in 2024 BioPharma days GMP QC Identity test Bringing the industry together as they Viruses – viral vectors – Conduct their evaluations of nanopore bacteria – other haploid organisms
Slide 20: We continue to innovate for research – and lock down for applied
We continue to innovate for research – and lock down for applied 01. 02. 03. 04. Q-Line Beta Registration based Open Early Released Locked down software & chemistry Early Access Access Robust platforms
Slide 21: 2025: An exciting year ahead
2025: An exciting year ahead Innovation roadmap Building on our strengths Upgrading and expanding our menu of end-to- Enriching the accuracy conversation PromethION output improvements end workflows from metrics to outcomes Price per Price per genome2 Price per genome2 ~$235 genome2 ~$345 300 Price
Slide 22: Things I'm excited about 2025
Things I’m excited about 2025 From innovation to transformation: Direct RNA Our innovation team create world leading Our customers explore Our team work with industry partners to create products applications today applied products for tomorrow "RNA sequencing long involved a proxy: analysis of cDNA.
Slide 23: Things I'm excited about 2025
Things I'm excited about 2025 From innovation to transformation: Our multi-omic journey Creating a new methylation standard Exploring the central dogma DNA RNA PROTEIN
Slide 24: Market Opportunity reflects Oxford Nanopore differentiated platform
Market Opportunity reflects Oxford Nanopore differentiated platform Current Opportunity: Biopharma Clinical Applied Long 10% Beyond term vision 10% Broader opportunities today’s market unlocked by: Towards anything, anyone, $7.5 51% • Richer multiomic data Richer molecular anywhere. billion insights
Slide 25: Medium term outlook: FY27 targets
Medium term outlook: FY27 targets >30% CAGR1 >62% 2027 Revenue Gross margin Adjusted EBITDA Medium term revenue Material scope for margin Breakeven profitability in FY27 with growth underpinned by improvement over the operational leverage set to improve further differentiated technology medium term
Slide 26: Key takeaways
Key takeaways FY24 results in-line with expectations; strong H2 growth underpins confidence in 2025+ Unique features and benefits driving platform adoption and utilisation; underpinning strong revenue performance Focus on core end markets, products and applications that can deliver growth in tough m
Slide 27: Thank you
Thank you Oxford Nanopore Technologies, the Wheel icon, AmPORE-TB, ElysION, EPI2ME, Flongle, GridION, MinION, MinKNOW, PromethION, and TraxION are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries. Information contained herein may
Oxford Nanopore Technologies — J.P. Morgan Healthcare Conference 2025 on 6ix